Homology Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
10-K Summary.
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Homology Medicines, Inc. | ||
| Date: March 12, 2024 | By: | /s/ Paul Alloway, Ph.D. |
|---|---|---|
| Paul Alloway, Ph.D. | ||
| President and Chief Operating Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Paul Alloway, Ph.D. | President and Chief Operating Officer(principal executive officer) | March 12, 2024 |
| Paul Alloway, Ph.D. | ||
| /s/ Charles Michaud, Jr. | Vice President, Corporate Controller and Treasurer(principal financial and accounting officer) | March 12, 2024 |
| Charles Michaud, Jr. | ||
| /s/ Arthur Tzianabos, Ph.D. | Chairman of the Board of Directors | March 12, 2024 |
| Arthur Tzianabos, Ph.D. | ||
| /s/ Jeffrey V. Poulton | Lead Independent Director | March 12, 2024 |
| Jeffrey V. Poulton | ||
| /s/ Steven Gillis, Ph.D. | Director | March 12, 2024 |
| Steven Gillis, Ph.D. | ||
| /s/ Matthew R. Patterson | Director | March 12, 2024 |
| Matthew R. Patterson | ||
| /s/ Alise S. Reicin, M.D. | Director | March 12, 2024 |
| Alise S. Reicin, M.D. | ||
| /s/ Mary Thistle | Director | March 12, 2024 |
| Mary Thistle | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive Loss | F-6 |
| Consolidated Statements of Stockholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.